Emtricitabine + Tenofovir Disoproxil Fumarate (Oral PrEP) [200 mg + 300 mg fixed dose combination film-coated tablet] for the prevention of sexually acquired HIV infection among at risk individuals
Pre-Cycle 1 | DrugsHTA Council Recommendation (as of 31 December 2021)
As final recommendation, the HTA Council recommends the inclusion of emtricitabine + tenofovir disoproxil fumarate (Oral PrEP) [200 mg + 300 mg fixed dose combination film-coated tablet] for the prevention of sexually acquired HIV infection among at risk individuals in the Philippine National Formulary (PNF).
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should emtricitabine + tenofovir disoproxil fumarate (Oral PrEP) [200 mg + 300 mg fixed dose combination film-coated tablet] for the prevention of sexually acquired HIV infection among at risk individuals be included in the Philippine National Formulary?
- Secretary of Health Decision: Approved on 20 January 2022
Evidence and Relevant Documents